How Advances in Genomics are Changing Patient Care

Nursing Clinics of North America

Volumn 48, Issue 4, 2013, Pages 557-569

  Bancroft, Elizabeth K ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Genetics; Genomics; Nursing; Practice implications

Indexed keywords

EDUCATION; GENETIC COUNSELING; GENETICS; GENOMICS; HEALTH SERVICE; HUMAN; HUMAN GENOME; MEDICAL GENETICS; NEOPLASM; NURSE ATTITUDE; NURSING; NURSING PRACTICE; NURSING PROCESS; ORGANIZATION AND MANAGEMENT; PERSONALIZED MEDICINE; PRACTICE IMPLICATIONS; REVIEW;

GENETICS; GENOMICS; NURSING; PRACTICE IMPLICATIONS;

GENETIC COUNSELING; GENETICS, MEDICAL; GENOME, HUMAN; GENOMICS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; NURSE'S PRACTICE PATTERNS; NURSE'S ROLE; NURSING PROCESS;

EID: 84888358032     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2013.08.002     Document Type: Review

References (70)

1. Lango H., Weedon M.N. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice?. JIntern Med 2008, 263(1):16-27.
2. Pearson H. Genetic testing for everyone. Nature 2008, 453(7195):570-571.
3. Javitt G.H., Hudson K. The right prescription for personalized genetic medicine. Personalized Medicine 2007, 4(2):115-118.
4. Zheng S.L., Sun J., Wiklund F., et al. Cumulative association of five genetic variants with prostate cancer. NEngl J Med 2007, 358:910-919.
5. Human Genomics Strategy Group Building on our inheritance: genomic technology in healthcare 2012, The Department of Health, Available at:, Accessed March 1, 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213705/dh_132382.pdf.
6. Collins F., McKusick V. Implications of the Human Genome Project for medical science. JAMA 2001, 285:540-544.
7. Burke W. Genetic testing in primary care. Annu Rev Genomics Hum Genet 2004, 5:1-14.
8. Samani N.J., Tomaszewski M., Schunkert H. The personal genome-the future of personalised medicine?. Lancet 2010, 375(9725):1497-1498.
9. Calzone K.A., Cashion A., Feetham S., et al. Nurses transforming health care using genetics and genomics. Nurs Outlook 2010, 58(1):26-35.
10. World Health Organisation. 2013. Available at: Accessed March 1, 2013. http://www.who.int.
11. Hall W.D., Mathews R., Morley K.I. Being more realistic about the public health impact of genomic medicine. PLoS Med 2010, 12(7):10.
12. Van Rijn M.J., van Duijn C.M., Slooter A.J. Impact of genetic testing on complex diseases. Eur J Epidemiol 2005, 20(5):383-388.
13. Witte J.S. Personalized prostate cancer screening: improving PSA tests with genomic information. Sci Transl Med 2010, 2(62):55.
14. Mihaescu R., Meigs J., Sijbrands E., et al. Genetic risk profiling for prediction of type 2 diabetes. PLoS Curr 2011, 11:3.
15. Cancer Research UK. 2013. Available at: Accessed March 1, 2013. http://www.cancerresearchuk.org/.
16. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers. JNatl Cancer Inst 2002, 94(18):1358-1365.
17. Cancer risks in BRCA2 mutation carriers. JNatl Cancer Inst 1999, 91(15):1310-1316. Breast Cancer Linkage Consortium.
18. Aarnio M., Mecklin J.P., Aaltonen L.A., et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64:430-433.
19. Pharoah P.D., Antoniou A.C., Easton D.F., et al. Polygenes, risk prediction, and targeted prevention of breast cancer. NEngl J Med 2008, 358(26):2796-2803.
20. Antoniou A.C., Easton D.F. Models of genetic susceptibility to breast cancer. Oncogene 2006, 25(43):5898-5905.
21. Feero W.G., Guttmacher A.E., Collins F.S. The genome gets personal-almost. JAm Med Assoc 2008, 299:1351-1352.
22. Khoury M.J., Gwinn M., Yoon P.W. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med 2007, 9:665-674.
23. Offit K. Genomic profiles for disease risk: predictive or premature?. JAm Med Assoc 2008, 299:1353-1355.
24. Pashayan N., Pharoah P. Translating genomics into improved population screening: hype or hope?. Hum Genet 2011, 130(1):19-21.
25. Pashayan N., Duffy S.W., Chowdhury S., et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011, 104(10):1656-1663.
26. Stewart A., Brice P., Burton H., et al. Genetics, health care and public policy 2007, Cambridge University Press, Cambridge (United Kingdom).
27. Lerman C., Shields A.E. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nat Rev Cancer 2004, 4(3):235-241.
28. Speicher M.R., Geigl J.B., Tomlinson I.P. Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. Lancet Oncol 2010, 11(9):890-898.
29. Pomerantz M.M., Freedman M.L. Genetics of prostate cancer risk. Mt Sinai J Med 2010, 77(6):643-654.
30. Ransohoff D.F., Khoury M.J. Personal genomics: information can be harmful. Eur J Clin Invest 2010, 40(1):64-68.
31. Bangma C.H., Roemeling S., Schröder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007, 25(1):3-9.
32. Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786.
33. Haga S.B., Khoury M.J., Burke W. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet 2003, 34:347-350.
34. Hunter D.J., Khoury M.J., Drazen J.M. Letting the genome out of the bottle-will we get our wish?. NEngl J Med 2008, 358(2):105-107.
35. Khoury M.J. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003, 5:261-268.
36. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304(9):967-975.
37. Pruthi S., Gostout B.S., Lindor N.M. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 2010, 85:1111-1120.
38. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706.
39. National Human Genome Research Institute. Personalized medicine: how the human genome era will usher in a health care revolution. 2005. Available at: Accessed March 1, 2013. http://www.genome.gov/13514107.
40. Kamali F., Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010, 61:63-75.
41. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005, 7:97-104.
42. McClain M.R., Palomaki G.E., Piper M., et al. Arapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008, 10(2):89-98.
43. Abdel-Razeq H., Marei L. Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 2011, 5:87-94.
44. Piccart-Gebhart M.J. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer 2006, 42:1715-1719.
45. Valachis A., Mauri D., Polyzos N.P., et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011, 20(6):485-490.
46. Green M.J., Botkin J.R. Genetic exceptionalism in medicine: clarifying the differences between genetic and non-genetic disease. Ann Intern Med 2003, 138:571-575.
47. Clark A., Ticehurst F. Living with the genome: ethical and social aspects of human genetics 1996, Palgrave Macmillan, Basingstoke (United Kingdom).
48. Smerecnik C.M., Mesters I., de Vries N., et al. Educating the general public about multifactorial genetic disease: applying a theory-based framework to understand current public knowledge. Genet Med 2008, 10(4):251-258.
49. Mesters I., Ausems A., De Vries H. General public's knowledge, interest and information needs related to genetic cancer: an exploratory study. Eur J Cancer Prev 2005, 14(1):69-75.
50. Davison C., Macintyre S., Smith G.D. The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed research agenda. Sociol Health Illn 1994, 16(3):340-371.
51. Calzone K.A. Genetic predisposition testing: clinical implications for oncology nurses. Oncol Nurs Forum 1997, 24:712-718.
52. Graves K.D., Peshkin B.N., Luta G., et al. Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. Public Health Genomics 2011, 14(3):178-189.
53. 23andMe. 2013. Available at: Accessed March 15, 2013. https://www.23andme.com/.
54. DeCODE. 2013. Available at: Accessed March 15, 2013. http://www.decodeme.com/.
55. Genetic Health. 2013. Available at: Accessed March 15, 2013. http://www.genetic-health.co.uk/.
56. Prainsack B., Reardon J., Hindmarsh R., et al. Personal genomes: misdirected precaution. Nature 2008, 456(7218):34-35.
57. Calzone K., Bowles-Biesecker B. Genetic testing for cancer predisposition. Cancer Nurs 2002, 25(1):15-25.
58. O'Daniel J., Haga S.B. Public perspectives on returning genetics and genomics research results. Public Health Genomics 2011, 14(6):346-355.
59. Koehly L.M., Peters J.A., Kenen R., et al. Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health education interventions. Am J Public Health 2009, 99(12):2203-2209.
60. Koehly L.M., Peters J.A., Kuhn N., et al. Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being. Psychooncology 2008, 17(8):812-821.
61. Finlay E., Stopfer J.E., Burlingame E. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test 2008, 12(1):81-91.
62. Lerman C., Marshall J., Audrain J., et al. Genetic testing for colon cancer susceptibility: anticipated reactions of patients and challenges to providers. Int J Cancer 1996, 69(1):58-61.
63. Billings P., Beckwith J. Genetic testing in the workplace: a view from the USA. Trends Genet 1992, 8(6):198-202.
64. American Association of Colleges of Nursing. The essentials of baccalaureate education for professional nursing practice. 2008. Available at: Accessed March 15, 2013. http://www.genome.gov/Pages/Careers/HealthProfessionalEducation/geneticscompetency.pdf.
65. National Coalition for Health Professional Education in Genetics. Core competencies in genetics essential for all health-care professionals. 2007. Available at: Accessed March 15, 2013. http://www.nchpeg.org/.
66. Bancroft E.K. Genetic testing for cancer predisposition and implications for nursing practice: narrative review. JAdv Nurs 2010, 66(4):710-737.
67. EuroGentest. Harmonising genetic testing across Europe. 2009. Available at: Accessed March 1, 2013. http://www.eurogentest.org/.
68. The National Genetics Education and Development Centre. 2009. Available at: Accessed March 1, 2013. http://www.geneticseducation.nhs.uk.
69. Genetics in Nursing & Midwifery Task and Finish Group Genetics/genomics in nursing and midwifery: Task and Finish Group report to the Nursing and Midwifery Professional Advisory Board 2011, The Department of Health, Available at:, Accessed March 1, 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215250/dh_131947.pdf.
70. Burke S., Kirk M. Genetics education in the nursing profession: literature review. JAdv Nurs 2006, 54(2):228-237.